Jenburkt Pharmaceuticals (524731) Q4 24/25 earnings summary

Executive summary

• Board approved audited standalone financials for Q4 and FY ended 31 March 2025, with unmodified audit opinion.

• Declared a final dividend of ₹18 (180%) per equity share for FY 2024-25.

• Scheduled 40th AGM for 18 July 2025 via video conferencing.

• Re-appointed Ashish Uttam Bhuta as Chairman & MD for five years from April 2026.

Financial highlights

• FY25 revenue from operations: ₹15,169.15 lakh, up from ₹14,196.65 lakh in FY24.

• FY25 net profit after tax: ₹3,206.06 lakh, up from ₹2,597.73 lakh in FY24.

• Q4 FY25 revenue: ₹4,104.69 lakh; Q4 net profit: ₹853.66 lakh.

• FY25 EPS: ₹72.65 vs ₹58.86 in FY24.

• Cash and cash equivalents at year-end: ₹736.48 lakh, up from ₹412.54 lakh.

Outlook and guidance

• Auditors confirmed no material uncertainty regarding the company's ability to meet liabilities as they fall due within one year from balance sheet date.

• No cash losses incurred in FY25 or the previous year.